Is anxiety a pathway to Alcohol Use Disorders? A phenome-wide association study of the GABRA2 coding variant rs279858

Alison K. Merikangas, Rachel L. Kember, Martin H. Plawecki, Chella Kamarajan, Grace Chan, Lance Bauer, Jacquelyn L. Meyers, John I. Nurnberger Jr, John Kramer, Bernice Porjesz, Howard J. Edenberg, Laura Almasy
doi: https://doi.org/10.1101/2022.11.21.22282301

Abstract

Alcohol use disorders (AUDs) and related electrophysiological endophenotypes have been associated with the GABRA2 gene. However, the causal variants in GABRA2 and their mechanisms of influence on AUD and its correlates have not been established. Here we investigate the phenotypic spectrum of a GABRA2 coding variant (rs279858) through a phenome-wide association study (PheWAS) in two open-source datasets.

We applied the PheWAS approach to identify a broad range of phenotypes associated with rs279858 in the MRC IEU OpenGWAS PheWAS and the Open Targets Genetics Portal. These databases extend the array of phenotypes beyond those available in electronic health records (EHR) to include numerous non-medical phenotypes and traits. We then followed up the results from those exploratory associations by examining the genetic correlations between our “top hits” and alcohol- and smoking-related phenotypes.

In both data sources, rs279858 (C effect allele) was associated with anxiety-related phenotypes, including reduced risk-taking behavior and an increase in nervous feelings, as well as reduced number of lifetime sexual partners. Follow-up analyses revealed that these phenotypes were genetically correlated with each other and with alcohol- and smoking-related phenotypes.

This work illustrates the utility of the PheWAS approach, particularly for phenotypes that extend beyond those that are typically captured in EHR data. In fact, the associations described here are all behavioral rather than clinical phenotypes. We postulate that these traits may be related to anxiety or behavioral inhibition that has been identified as a risk factor for AUD, and may represent pathophysiological intermediaries between GABRA2 and AUD.

Introduction

Alcohol Use Disorder (AUD) is a complex condition defined by a pattern of unhealthy, problematic use of alcohol with significant clinical impairment. There are both genetic and environmental contributions to its development. AUD has considerable public health, social, and economic costs with an estimated 5.9% of people meeting past-year criteria [1] and 13.8% in the United States meeting criteria for lifetime AUD [2]. Despite a reported heritability of nearly 50%, and substantial effort to establish the underlying genetic etiology, few genes aside from the alcohol metabolizing genes ADH1B and ALDH2 have been consistently associated with AUD in population-based genome-wide association studies (GWAS)[3]. However, a recent large meta-analysis including 435,563 individuals of European descent has now identified 29 associated loci for ‘problematic alcohol use’ (PAU)[4].

Both linkage and association studies of samples enriched for AUD have implicated the gene encoding gamma-aminobutyric acid type A receptor subunit alpha2 (GABRA2) in the etiology of alcohol use disorder [5-8]. The gamma-aminobutyric acid receptor subunit alpha-2 protein is a subunit of the GABA-A receptor. RNA-seq studies have demonstrated higher GABRA2 expression in brain, kidney, and small intestine as comparted to other body tissues [9,10]. GABRA2 has also been implicated in EEG changes in those with AUD, especially the beta rhythm of the resting EEG [5,11,12]. GABRA2 may act via neuromodulation since it has been associated with both AUD and EEG phenotypes [5].

In addition to AUD, associations have been reported between GABRA2 and several substance misuse phenotypes, including vulnerability to both nicotine dependence (ND) and cannabis dependence (CD)[13] as well as subjective response to alcohol and other alcohol-related reward processes [14,15]. GABRA2 has also been implicated in the disrupted structural connectome of reward circuits in heroin abusers [16], and in other neuropsychiatric-related phenotypes, including epilepsy [17], age at onset of Alzheimer’s disease [18], and risk-taking behavior [19], as well as antipsychotic-associated weight gain [20].

Though multiple single nucleotide polymorphisms (SNPs) within GABRA2 have been associated with both alcohol use and electrophysiological phenotypes, multiple studies have shown the strongest association signal for rs279858 and SNPs that are in linkage disequilibrium (LD) with this lead variant [5,21]. The rs279858 SNP in GABRA2 is one of the few loci from the candidate gene analysis era that was associated with alcohol dependence in the Study of Alcohol Addiction: Genetics and Addiction (SAGE)[8]. Specifically, G/G carriers appear to be more prone to AUD than A/A or A/G carriers [22,23]. However, in some publications, genotypes were called from the complementary DNA strand with alleles C and T, in which case the C allele is the one associated with higher risk. A functional role for this synonymous change in rs279858 has not been established. Researchers have postulated that its actions involve the modulation of both cognition and reward systems [16]. However, this SNP has not been associated with AUD in the largest case-control GWAS of AUD [4] and PAU [24] to date, but it has been implicated in phenotypic manifestations of alcohol use in some race/ethnicity subgroups [25] and in sex-specific analyses [26].

In parallel to the GWAS approach that attempts to identify markers that may influence the risk of AUD across the genome, phenome-wide association studies (PheWAS) are employed to identify a range of phenotypes that may be associated with a particular genetic variant. PheWAS test the association between a genetic variant (e.g., a SNP, gene, or polygenic score), and an array of phenotypes that range from International Classification of Diseases (ICD) codes in electronic health records (EHR)[27,28] to data from epidemiologic studies and biobanks that have been supplemented with questionnaires that assess lifestyle and behavioral traits [29]. PheWAS can identify associations of risk loci with novel traits that have not been previously linked to AUD. This data-driven approach can highlight numerous additional traits or conditions that may be associated with a genetic variant that might not have been investigated in analyses driven by known relationships among phenotypes. The PheWAS approach, e.g., PheWAS of polygenic scores [30,31] and other AUD-associated variants [32] has also been employed to elucidate comorbid conditions that may also contribute to the developmental trajectory of AUD.

Here we apply the PheWAS approach to several open-source tools in order to examine the phenotypic spectrum of an AUD-associated GABRA2 coding variant (rs279858) that may provide indices of potential causal systems and pathways. We employ three approaches to address the exploratory nature of this work including: a) correcting for multiple comparisons; b) conducting a “pseudo” replication by using two curated databases containing multiple large studies; and c) inspecting the genetic correlations within the identified phenotypes and between these phenotypes and alcohol-related phenotypes.

Materials and Methods

PheWAS data sources

The PheWAS approach [27] was used to investigate the range of phenotypes associated with rs279858 using two online tools; the Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol OpenGWAS PheWAS tool [33] (https://gwas.mrcieu.ac.uk/phewas/), and the Open Targets Genetics Portal [34] (https://genetics.opentargets.org/). Supplementary Table 3 lists the included data sources for both tools.

The MRC IEU OpenGWAS PheWAS queries a manually curated collection of eighteen batches of GWAS summary datasets encompassing over 14,000 individual GWAS that includes the UK Biobank (UKBB) and other national databases such as the Japanese Biobank [35] (https://biobankjp.org/en/), and FinnGen (https://www.finngen.fi/en), as well as the National Human Genome Research Institute (NHGRI)-European Bioinformatics Institute (EBI) GWAS Catalog summary statistics database. We searched rs279895 using their tool (https://gwas.mrcieu.ac.uk/phewas/), which only reports results filtered to p≤0.001, and then used the ieugwasr R package (R version 4.0.4) to connect to the application programming interface (API) and downloaded the complete results file (version 3.8.5).

The Open Targets Genetics Portal includes data from FinnGen (https://www.finngen.fi/en), the National Human Genome Research Institute (NHGRI)-European Bioinformatics Institute (EBI) GWAS Catalog summary statistics database [36] (GWAS Catalog, https://www.ebi.ac.uk/gwas/), and UKBB (http://www.nealelab.is/uk-biobank). We searched rs279858 on the Open Targets Genetics site (https://genetics.opentargets.org/, version 22.02) which maps this SNP to its location GRCh38: 4:46,312,576 (GRCh37: 4:46,314,593, https://genetics.opentargets.org/variant/4_46312576_T_C). Only traits associated at p<0.005 are returned and used for analysis.

PheWAS statistical significance

Some traits that have been examined in independent GWAS analyses of the biobanks have also been deposited in the GWAS Catalog. Therefore, traits may appear in both the OpenGWAS and Open Targets results, and on occasion multiple times in each. For such situations, we opted to retain the results from the instance with the smallest p-value. We adjusted the p-value to correct for the 16482 traits that appeared in the downloadable OpenGWAS dataset, which resulted in a Bonferroni-corrected significance threshold for this study of p<4.00×10−6. The Open Targets tool provides a Bonferroni-corrected phenome-wide significance threshold of p<9.77×10−5. The overlap in contributing data sources in shown in Supplementary Table 3.

SNP-based heritability

In order to determine the likelihood of detecting genetic signals for alcohol-related phenotypes in the UKBB, we examined the SNP-based heritability (h2) in the UKBB generated by the Neale Lab [37]. They provide an automated calculation of SNP-heritability via partitioned linkage disequilibrium score regression (LDSC)[38], with h2 values using a liability scale for binary phenotypes. We used this information to gauge the overall genetic signal for UKBB alcohol-related phenotypes queried in our PheWAS analysis, by examining the heritability and statistical significance of component items of the Alcohol Use Disorders Identification Test (AUDIT)[39] present in the UKBB.

Genetic correlation

We used results generated by the Neale Lab on the genetic correlation (rg) between phenotypes in the UKBB via LDSC (https://ukbb-rg.hail.is/) to explore unexpected results from the PheWAS. Statistically significant phenotypes from the PheWAS analyses were compared to one another, and to the available alcohol, tobacco, and cannabis use phenotypes. This information can be used to evaluate whether the identified phenotype may be indexing another trait that does not demonstrate statistical significance due to sample size. A Bonferroni corrected p-value of 2.92×10−4 was employed to correct for the number of correlations that we examined across the selected traits (171 pairs).

Results

The PheWAS results at p<0.005 from both the MRC IEU OpenGWAS and the Open Targets PheWAS are shown in Supplementary Table 1 and 2, respectively. Supplementary Table 3 lists the data sources and highlights their overlapping and independent contributions to the results presented here.

MRC IEU OpenGWAS

The strongest associations for rs279858 (C effect allele) were with reduced risk-taking behavior, an increase in nervous feelings, reduced number of lifetime sexual partners, and reduced length of mobile phone use. Table 1 shows the top ten associations of rs279858 in the IEU analysis. For traits that appeared more than once, the instance with the smallest p-value was retained. Figure 1a and Supplementary Table 1 show the complete results at p<0.005.

View this table:
Table 1:

Top ten associations of rs279858 in the OpenGWAS Analysis.

Figure 1:
Figure 1: OpenGWAS and Open Targets rs279858 PheWAS plots

Phenome-wide association study results for rs279858 from the OpenGWAS PheWAS tool (a) and the Open Targets PheWAS tool (b). Traits with a p-value p<0.005 are shown, with the down arrow representing a negative beta, and the up arrow representing a positive beta (C effect allele). In (a) the dashed red line represents a Bonferroni-corrected phenome-wide significance threshold of p<4.00×10−6. In (b) the dashed red line represents a Bonferroni-corrected phenome-wide significance threshold of p<9.77×10−5

Open Targets Genetics

In the Open Targets analysis, rs279858 (C effect allele) was associated with a reduced level of self-reported number of lifetime sexual partners, reduced risk-taking behavior, an increase in nervous feelings, a lower Townsend deprivation index at recruitment (a measure of socioeconomic status within a population encompassing employment, car and home ownership, and household overcrowding by post code)[41], getting up earlier in the morning, never/rarely having milk, and a reduced length of mobile phone use. Table 2 shows the top ten associations for rs279858 in the Open Targets analysis. Figure 1b and Supplementary Table 2 show the complete results at p<0.005. No alcohol, tobacco, or other substance use phenotypes were among the top rs279858 associations in either PheWAS.

View this table:
Table 2:

Top ten associations of rs279858 in the Open Targets Analysis.

SNP-based heritability of AUDIT phenotypes in UKBB

Table 3 shows the AUDIT items in the UKBB, their SNP-based heritability, associated p-value, and the sample size for each item. The final column shows the p-value that was generated for that item in our MRC IEU OpenGWAS PheWAS analysis. The AUDIT items that showed statistically significant SNP-based heritability included: “Frequency of drinking alcohol”; “Amount of alcohol drunk on a typical drinking day”; and “Frequency of consuming six or more units of alcohol”. Notably, not all of the AUDIT items were included in the PheWAS, and the ones that were included were not associated with rs279858.

View this table:
Table 3:

Heritability of alcohol phenotypes in the UKBB from the MRC IEW OpenGWAS PheWAS

Genetic correlation

The genetic correlations between the statistically significant UKBB phenotypes from the PheWAS, and UKBB alcohol, tobacco, and substance use phenotypes are shown in Figure 2 (also see the full results in Supplementary Table 4). After a conservative Bonferroni correction (p<2.92×10−4), statistically significant genetic correlations were observed among the majority of the PheWAS phenotypes with the exception of the dietary phenotypes [i.e., “Milk type used: Never/rarely have milk” and “Cereal type: Oat cereal (e.g., Ready Brek, porridge)]”, which were nominally correlated with the other PheWAS traits (p<0.05) but did not survive correction for multiple testing. The top hits from the PheWAS were also genetically correlated with most of the smoking and alcohol phenotypes at a standard p<0.05. However, “Getting up in morning”, “Nervous feelings”, and the dietary phenotypes were not genetically correlated with smoking after employing correction for multiple comparisons. Similarly, fewer of the top hits were genetically correlated with alcohol phenotypes after control for multiple comparisons. Notably, “nervous feelings” was not genetically correlated with alcohol use. In addition, risk-taking and lifetime number of sexual partners were genetically correlated with being a previous drinker.

Figure 2:
Figure 2: Genetic correlations among top UKBB rs279858 PheWAS hits, alcohol, and smoking phenotypes

The genetic correlations between the top rs279858-associated phenotypes, alcohol, and smoking phenotypes in the UKBB are shown. A single asterisk represents a nominally significant p-value p<0.05, and a double asterisk represents a p-value that meets the Bonferroni corrected threshold of p-value p<2.92×10−4. The darker blue represents a negative correlation, while the darker red represents a positive correlation.

Discussion

In both open-source PheWAS analyses, the C allele of rs279858, the top AUD SNP within a GABRA2 LD block, was associated with an increase in nervous feelings, a reduced level of self-reported risk-taking behavior, reduced number of lifetime sexual partners, and shorter duration of mobile phone use. We postulate that these traits may be related to reduced novelty seeking/behavioral inhibition or anxiety that has been identified as a risk factor for alcohol misuse [43,44]. These phenotypes have been shown to underlie anxiety-related symptoms and disorders that have been involved in pathways to AUD [45]. Our analyses of the genetic correlations both within these the anxiety/inhibition phenotypes as well with a large number of alcohol related behaviors suggests that the phenotypic links may share overall genetic architecture with AUD in addition to their common association with rs279858.

This work builds upon the substantial body of research that has attempted to identify genetic and environmental risk factors that may inform the multifactorial architecture of AUD. The broad range of phenotypes examined in these PheWAS tools, and particularly in the UKBB, extend far beyond those that are typically captured in EHR data. It is also notable that the effect sizes for the behavioral traits are quite small (∼0.005-0.05), which may explain why these associations are only seen in large samples.

The strongest associations that survived correction for multiple comparisons were for anxiety phenotypes and reduced novelty seeking/behavioral inhibition. The association between rs279858 C allele and the anxiety phenotypes in the PheWAS confirms the links between AUD and anxiety disorders, particularly social anxiety, reported in earlier family [46,47] and twin studies [48]. Furthermore, specific anxiety disorder subtypes have been shown to elevate the risk of subsequent onset of both alcohol use and dependence in community surveys worldwide [2,49]. The heterogeneity and complexity of this association has been described in several earlier reviews [50,51]. The convergence of our PheWAS findings with these genetic epidemiologic studies suggests that inquiry into potential mechanisms for the role of genetic factors indexed by this SNP may inform this potential pathway to AUD.

Our finding of the associations between anxiety related phenotypes with the C allele of rs279858 is consistent with reports of an association between externalizing behavior, including substance use and greater risk taking, with the opposite T allele of rs279858 allele [52-56]. In contrast, direct tests of association show that the C allele is associated with AUD [5,21,52]. Analyses of an adolescent sample [52] revealed indirect associations of AUD with the T allele through externalizing factors and direct associations of problematic alcohol use with the C allele. This suggests that the role of GABRA2 in AUD may be multi-faceted and developmentally expressed. In the large nationally representative sample of adults in the National Comorbidity Survey [57], anxiety and externalizing were each independently associated with higher risk of AUD, but there was a potential interactive effect between anxiety and externalizing disorders that was associated with reduced rates of AUD.

The lack of an association between rs279858 with alcohol traits assessed in the UKBB [(e.g., consumption measures (alcohol intake frequency, p=0.69) and self-reported alcohol use problems (ever addicted to alcohol, p=0.04)] was not surprising given the lack of previous associations between rs279858 and AUD phenotypes in general population-based samples that were not recruited for substance use disorder studies. However, these analyses do show strong genetic correlations between our top PheWAS hits and alcohol and smoking phenotypes in UKBB. A potential explanation may be that the association of alcohol phenotypes with GABRA2 has been found in samples enriched for AUD but not in a volunteer sample of older adults such as the UKBB, which is predominantly female and among which there was a low frequency of AUD. Another consideration is that a smaller proportion of participants completed some of the alcohol use modules in the UKBB, meaning that these traits have smaller sample sizes than the ones identified in our PheWAS.

GABRA2 has been associated with a number of other traits in GWAS, including epilepsy [17,58], post bronchodilator FEV1/FVC ratio [59], Alzheimer disease and age of onset [18], Mononucleosis [60], general cognitive ability [61], general risk tolerance (MTAG) [19], adventurousness [19], protein quantitative trait loci (liver)[62], and Type 1 diabetes (age at diagnosis)[63]. It is notable that the association findings for general cognitive ability, general risk tolerance, and adventurousness were found in UKBB data. These traits are composite phenotypes formed from the UKBB traits identified in our PheWAS that include nervous feelings and reduced risk-taking and lend credence to the theory that the impact of GABRA2 on alcohol-related phenotypes is through anxiety or risk taking.

The effects of the GABRA2 gene in basic animal model studies provide intriguing parallels to our findings. Numerous phenotypes that overlap our association findings have been found in GABRA2 knockout mice [64] (http://www.informatics.jax.org/marker/phenotypes/MGI:95614). In particular, GABRA2 has been shown to impact parallel behavioral phenotypes in mice, including increased anxiety-related response and an abnormal conditioned emotional response, as well as medical phenotypes in the immune and nervous systems (Supplementary Table 5). Moreover, GABRA2 has been related to hypersensitivity to the acute effects of alcohol [65] and is a binding site for benzodiazepines known to decrease anxiety [66]. There is further indirect evidence that neuroactive steroids may be involved in some of the subjective effects of alcohol reflecting the role of this SNP on both immune function and alcohol and benzodiazepine effects and metabolism [25,67-69]. It would be interesting to examine the impact of this marker on the preliminary evidence for the efficacy of gabapentin, a gamma aminobutyric acid (GABA) analogue, in the treatment of AUD [70].

Strengths & limitations

The main strength of this study is the application of the PheWAS approach to identify potential influences of the GABRA2 gene that extend beyond the diagnostic code-based EHR. We include a wide range of other biological and social phenotypes that may reflect the multifactorial etiology of AUD.

This work has several limitations that should be considered in interpreting these findings. First, phenotypes can appear multiple times in the same database or in different databases. This leads to a lack of independence in the analyses, which creates a challenge for appropriately adjusting for multiple comparisons, meaning the Bonferroni method is extremely conservative in this case. Second, the wide range of phenotypes that extend beyond medically relevant conditions to include behavior, temperamental traits, and social variables may include variables that are neither empirical or conceptual correlates of AUD. This may make it difficult to interpret the results in the context of AUD, as exemplified by the associations with dietary phenotypes. Third, there is overlap in the two databases that were used for these analyses. Although the use of the UKBB data is a strength of this study, it is also a limitation because these findings may have overshadowed those of the smaller studies. Fourth, the applicability of this approach for understanding mechanisms of AUD relies on the relevance of the GABRA2 gene, which although shown in both enriched samples and basic animal model studies, has not been identified in the large GWAS studies of AUD. Nevertheless, the similarity in the phenotypic findings from the PheWAS and the knockout mouse studies suggest that we may be honing in on relevant phenotypic manifestations of this gene.

Conclusion

In conclusion, we have shown that rs279858 (C effect allele) is associated with anxiety phenotypes, which may represent pathophysiological intermediaries between GABRA2 and AUD. If replicated, these findings would confirm the utility of identifying anxiety as a target of prevention and intervention of AUD. Future in depth investigation of the potential genetic and biologic mechanisms for the link between this genetic system and its correlates in the development of AUD is warranted.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Funding and Disclosure

Support for the work presented here was provided by the Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401). The authors declare no conflicts of interest.

Author Contributions

Conceptualized study: AKM, LA; Conducted analyses: AKM, RLK; Drafted manuscript: AKM, LA; Reviewed and edited manuscript: LA, LB, CG, HJE, CK, RLK, JK, AKM, JLM, JN, MHP, BP.

Supplemental Material

Table S1: OpenGWAS rs279858 PheWAS results for p<0.005

Table S2: Open Targets rs279858 PheWAS results for p<0.005

Table S3: OpenGWAS and Open Targets PheWAS data sources

Table S4: Genetic correlations between the statistically significant UKBB phenotypes from the PheWAS, and UKBB alcohol, tobacco, and substance use phenotypes

Table S5: GABRA2 Mammalian Phenotype Ontology Annotations (MGI:95614)

Acknowledgments

The support of Hannah L. Bocchinfuso, Resource Coordinator for the Almasy Lab, is invaluable. We are indebted to all of the researchers who deposit their data into central repositories, and those who developed the online tools used to complete this research.

The Collaborative Study on the Genetics of Alcoholism (COGA), Principal Investigators B. Porjesz, V. Hesselbrock, T. Foroud; Scientific Director, A. Agrawal; Translational Director, D. Dick, includes eleven different centers: University of Connecticut (V. Hesselbrock); Indiana University (H.J. Edenberg, T. Foroud, Y. Liu, M. Plawecki); University of Iowa Carver College of Medicine (S. Kuperman, J. Kramer); SUNY Downstate Health Sciences University (B. Porjesz, J. Meyers, C. Kamarajan, A. Pandey); Washington University in St. Louis (L. Bierut, J. Rice, K. Bucholz, A. Agrawal); University of California at San Diego (M. Schuckit); Rutgers University (J. Tischfield, R. Hart, J. Salvatore); The Children’s Hospital of Philadelphia, University of Pennsylvania (L. Almasy); Virginia Commonwealth University (D. Dick); Icahn School of Medicine at Mount Sinai (A. Goate, P. Slesinger); and Howard University (D. Scott). Other COGA collaborators include: L. Bauer (University of Connecticut); J. Nurnberger Jr., L. Wetherill, X., Xuei, D. Lai, S. O’Connor, (Indiana University); G. Chan (University of Iowa; University of Connecticut); D.B. Chorlian, J. Zhang, P. Barr, S. Kinreich, G. Pandey (SUNY Downstate); N. Mullins (Icahn School of Medicine at Mount Sinai); A. Anokhin, S. Hartz, E. Johnson, V. McCutcheon, S. Saccone (Washington University); J. Moore, Z. Pang, S. Kuo (Rutgers University); A. Merikangas (The Children’s Hospital of Philadelphia and University of Pennsylvania); F. Aliev (Virginia Commonwealth University); H. Chin and A. Parsian are the NIAAA Staff Collaborators. We continue to be inspired by our memories of Henri Begleiter and Theodore Reich, founding PI and Co-PI of COGA, and also owe a debt of gratitude to other past organizers of COGA, including Ting-Kai Li, P. Michael Conneally, Raymond Crowe, and Wendy Reich, for their critical contributions. This national collaborative study is supported by NIH Grant U10AA008401 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA).

References

  1. ↵
    Ahrnsbrak R, Bose J, Hedden SL, Lipari RN, Park-Lee E. Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2017;1572.
  2. ↵
    Glantz MD, Bharat C, Degenhardt L, Sampson NA, Scott KM, Lim CCW, et al. The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys. Addict Behav. 2020;102:106128.
    OpenUrl
  3. ↵
    Deak JD, Miller AP, Gizer IR. Genetics of alcohol use disorder: a review. Curr Opin Psychol. 2019;27:56–61.
    OpenUrl
  4. ↵
    Zhou H, Sealock JM, Sanchez-Roige S, Clarke TK, Levey DF, Cheng Z, et al. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nat Neurosci. 2020;23(7):809–18.
    OpenUrl
  5. ↵
    Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO, et al. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet. 2004;74(4):705–14.
    OpenUrlCrossRefPubMedWeb of Science
  6. Reich T, Edenberg HJ, Goate A, Williams JT, Rice JP, Van Eerdewegh P, et al. Genome-wide search for genes affecting the risk for alcohol dependence. Am J Med Genet. 1998;81(3):207–15.
    OpenUrlCrossRefPubMedWeb of Science
  7. Covault J, Gelernter J, Hesselbrock V, Nellissery M, Kranzler HR. Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet. 2004;129b(1):104–9.
    OpenUrlCrossRefPubMed
  8. ↵
    Olfson E, Bierut LJ. Convergence of genome-wide association and candidate gene studies for alcoholism. Alcohol Clin Exp Res. 2012;36(12):2086–94.
    OpenUrlCrossRefPubMed
  9. ↵
    National Library of Medicine. GABRA2 gamma-aminobutyric acid type A receptor subunit alpha2 [Homo sapiens (human)]. 2022. https://www.ncbi.nlm.nih.gov/gene/2555. Accessed 12022-06-03 2022.
  10. ↵
    Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13(2):397–406.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Lydall GJ, Saini J, Ruparelia K, Montagnese S, McQuillin A, Guerrini I, et al. Genetic association study of GABRA2 single nucleotide polymorphisms and electroencephalography in alcohol dependence. Neurosci Lett. 2011;500(3):162–6.
    OpenUrlCrossRefPubMed
  12. ↵
    Porjesz B, Almasy L, Edenberg HJ, Wang K, Chorlian DB, Foroud T, et al. Linkage disequilibrium between the beta frequency of the human EEG and a GABAA receptor gene locus. Proc Natl Acad Sci U S A. 2002;99(6):3729–33.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Philibert RA, Gunter TD, Beach SR, Brody GH, Hollenbeck N, Andersen A, et al. Role of GABRA2 on risk for alcohol, nicotine, and cannabis dependence in the Iowa Adoption Studies. Psychiatr Genet. 2009;19(2):91–8.
    OpenUrlPubMed
  14. ↵
    Roh S, Matsushita S, Hara S, Maesato H, Matsui T, Suzuki G, et al. Role of GABRA2 in moderating subjective responses to alcohol. Alcohol Clin Exp Res. 2011;35(3):400–7.
    OpenUrlCrossRefPubMed
  15. ↵
    Arias AJ, Covault J, Feinn R, Pond T, Yang BZ, Ge W, et al. A GABRA2 variant is associated with increased stimulation and ‘high’ following alcohol administration. Alcohol Alcohol. 2014;49(1):1–9.
    OpenUrlCrossRefPubMed
  16. ↵
    Sun Y, Zhang Y, Zhang D, Chang S, Jing R, Yue W, et al. GABRA2 rs279858-linked variants are associated with disrupted structural connectome of reward circuits in heroin abusers. Transl Psychiatry. 2018;8(1):138.
    OpenUrl
  17. ↵
    International League Against Epilepsy Consortium on Complex Epilepsies. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol. 2014;13(9):893–903.
    OpenUrlCrossRefPubMed
  18. ↵
    Herold C, Hooli BV, Mullin K, Liu T, Roehr JT, Mattheisen M, et al. Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer’s disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry. 2016;21(11):1608–12.
    OpenUrlCrossRef
  19. ↵
    Karlsson Linnér R, Biroli P, Kong E, Meddens SFW, Wedow R, Fontana MA, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nat Genet. 2019;51(2):245–57.
    OpenUrl
  20. ↵
    Zai CC, Tiwari AK, Chowdhury NI, Brandl EJ, Shaikh SA, Freeman N, et al. Association study of GABAA alpha2 receptor subunit gene variants in antipsychotic-associated weight gain. J Clin Psychopharmacol. 2015;35(1):7–12.
    OpenUrl
  21. ↵
    Li D, Sulovari A, Cheng C, Zhao H, Kranzler HR, Gelernter J. Association of gamma-aminobutyric acid A receptor alpha2 gene (GABRA2) with alcohol use disorder. Neuropsychopharmacology. 2014;39(4):907–18.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Dick DM, Cho SB, Latendresse SJ, Aliev F, Nurnberger JI, Jr.., Edenberg HJ, et al. Genetic influences on alcohol use across stages of development: GABRA2 and longitudinal trajectories of drunkenness from adolescence to young adulthood. Addict Biol. 2014;19(6):1055–64.
    OpenUrl
  23. ↵
    Villafuerte S, Heitzeg MM, Foley S, Yau WY, Majczenko K, Zubieta JK, et al. Impulsiveness and insula activation during reward anticipation are associated with genetic variants in GABRA2 in a family sample enriched for alcoholism. Mol Psychiatry. 2012;17(5):511–9.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Jorgenson E, Thai KK, Hoffmann TJ, Sakoda LC, Kvale MN, Banda Y, et al. Genetic contributors to variation in alcohol consumption vary by race/ethnicity in a large multi-ethnic genome-wide association study. Mol Psychiatry. 2017;22(9):1359–67.
    OpenUrlCrossRefPubMed
  25. ↵
    Koulentaki M, Kouroumalis E. GABAA receptor polymorphisms in alcohol use disorder in the GWAS era. Psychopharmacology (Berl). 2018;235(6):1845–65.
    OpenUrlCrossRef
  26. ↵
    Moe JS, Bolstad I, Morland JG, Bramness JG. GABAA subunit single nucleotide polymorphisms show sex-specific association to alcohol consumption and mental distress in a Norwegian population-based sample. Psychiatry Res. 2022;307:114257.
    OpenUrl
  27. ↵
    Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010;26(9):1205–10.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013;31(12):1102–10.
    OpenUrlCrossRefPubMed
  29. ↵
    Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-phenome relationship using phenome-wide association studies. Nat Rev Genet. 2016;17(3):129–45.
    OpenUrlCrossRefPubMed
  30. ↵
    Hartwell EE, Merikangas AK, Verma SS, Ritchie MD, Regeneron Genetics Center, Kranzler HR, et al. Genetic liability for substance use associated with medical comorbidities in electronic health records of African- and European-ancestry individuals. Addict Biol. 2021:e13099.
  31. ↵
    Kember RL, Merikangas AK, Verma SS, Verma A, Judy R, Regeneron Genetics C, et al. Polygenic Risk of Psychiatric Disorders Exhibits Cross-trait Associations in Electronic Health Record Data From European Ancestry Individuals. Biol Psychiatry. 2021;89(3):236–45.
    OpenUrl
  32. ↵
    Polimanti R, Kranzler HR, Gelernter J. Phenome-Wide Association Study for Alcohol and Nicotine Risk Alleles in 26394 Women. Neuropsychopharmacology. 2016;41(11):2688–96.
    OpenUrl
  33. ↵
    Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv. 2020:2020.08.10.244293.
  34. ↵
    Ghoussaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, et al. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic Acids Res. 2021;49(D1):D1311–D20.
    OpenUrlPubMed
  35. ↵
    Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, et al. Overview of the BioBank Japan Project: Study design and profile. Journal of epidemiology. 2017;27(3S):S2–S8.
    OpenUrlCrossRefPubMed
  36. ↵
    Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005–d12.
    OpenUrlCrossRefPubMed
  37. ↵
    Walters R. Updating SNP heritability results from 4,236 phenotypes in UK biobank. 2019. https://www.nealelab.is/blog/2019/10/24/updating-snp-heritability-results-from-4236-phenotypes-in-uk-biobank. Accessed 2022-06-03 2022.
  38. ↵
    Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics C, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291–5.
    OpenUrlCrossRefPubMed
  39. ↵
    Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993;88(6):791–804.
    OpenUrlCrossRefPubMedWeb of Science
  40. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73–79.
    OpenUrlCrossRefPubMed
  41. ↵
    Townsend P, Phillimore P, Beattie A. Health and deprivation: Inequality and the North. Routledge: London; 1988.
  42. Nagel M, Watanabe K, Stringer S, Posthuma D, van der Sluis S. Item-level analyses reveal genetic heterogeneity in neuroticism. Nat Commun. 2018;9(1):905.
    OpenUrl
  43. ↵
    Schuckit MA, Tipp JE, Bucholz KK, Nurnberger JI, Jr.., Hesselbrock VM, Crowe RR, et al. The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction. 1997;92(10):1289–304.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    Gorka SM, Shankman SA, Olino TM, Seeley JR, Kosty DB, Lewinsohn PM. Anxiety disorders and risk for alcohol use disorders: the moderating effect of parental support. Drug and alcohol dependence. 2014;140:191–97.
    OpenUrl
  45. ↵
    Anker JJ, Kushner MG. Co-Occurring Alcohol Use Disorder and Anxiety: Bridging Psychiatric, Psychological, and Neurobiological Perspectives. Alcohol Res. 2019;40(1).
  46. ↵
    Merikangas KR, Angst J, Eaton W, Canino G, Rubio-Stipec M, Wacker H, et al. Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. Br J Psychiatry Suppl. 1996(30):58–67.
  47. ↵
    Merikangas KR, Stevens DE, Fenton B, Stolar M, O’Malley S, Woods SW, et al. Co-morbidity and familial aggregation of alcoholism and anxiety disorders. Psychol Med. 1998;28(4):773–88.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    Torvik FA, Rosenström TH, Gustavson K, Ystrom E, Kendler KS, Bramness JG, et al. Explaining the association between anxiety disorders and alcohol use disorder: A twin study. Depress Anxiety. 2019;36(6):522–32.
    OpenUrlCrossRef
  49. ↵
    Schneier FR, Foose TE, Hasin DS, Heimberg RG, Liu SM, Grant BF, et al. Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2010;40(6):977–88.
    OpenUrlCrossRefPubMed
  50. ↵
    Kushner MG, Abrams K, Borchardt C. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev. 2000;20(2):149–71.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    Swendsen J, Le Moal M. Individual vulnerability to addiction. Ann N Y Acad Sci. 2011;1216:73–85.
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    Wang FL, Chassin L, Geiser C, Lemery-Chalfant K. Mechanisms in the relation between GABRA2 and adolescent externalizing problems. Eur Child Adolesc Psychiatry. 2016;25(1):67–80.
    OpenUrl
  53. Dick DM, Bierut L, Hinrichs A, Fox L, Bucholz KK, Kramer J, et al. The role of GABRA2 in risk for conduct disorder and alcohol and drug dependence across developmental stages. Behav Genet. 2006;36(4):577–90.
    OpenUrlCrossRefPubMedWeb of Science
  54. Dick DM, Latendresse SJ, Lansford JE, Budde JP, Goate A, Dodge KA, et al. Role of GABRA2 in trajectories of externalizing behavior across development and evidence of moderation by parental monitoring. Arch Gen Psychiatry. 2009;66(6):649–57.
    OpenUrlCrossRefPubMedWeb of Science
  55. Salvatore JE, Meyers JL, Yan J, Aliev F, Lansford JE, Pettit GS, et al. Intergenerational continuity in parents’ and adolescents’ externalizing problems: The role of life events and their interaction with GABRA2. J Abnorm Psychol. 2015;124(3):709–28.
    OpenUrl
  56. ↵
    Karlsson Linnér R, Mallard TT, Barr PB, Sanchez-Roige S, Madole JW, Driver MN, et al. Multivariate analysis of 1.5 million people identifies genetic associations with traits related to self-regulation and addiction. Nat Neurosci. 2021;24(10):1367–76.
    OpenUrl
  57. ↵
    Hofmann SG, Richey JA, Kashdan TB, McKnight PE. Anxiety disorders moderate the association between externalizing problems and substance use disorders: data from the National Comorbidity Survey-Revised. J Anxiety Disord. 2009;23(4):529–34.
    OpenUrlCrossRefPubMed
  58. ↵
    International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun. 2018;9(1):5269.
    OpenUrlCrossRefPubMed
  59. ↵
    Lutz SM, Cho MH, Young K, Hersh CP, Castaldi PJ, McDonald ML, et al. A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. BMC Genet. 2015;16:138.
    OpenUrlCrossRefPubMed
  60. ↵
    Tian C, Hromatka BS, Kiefer AK, Eriksson N, Noble SM, Tung JY, et al. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. Nat Commun. 2017;8(1):599.
    OpenUrlCrossRefPubMed
  61. ↵
    Davies G, Lam M, Harris SE, Trampush JW, Luciano M, Hill WD, et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat Commun. 2018;9(1):2098.
    OpenUrlCrossRefPubMed
  62. ↵
    He B, Shi J, Wang X, Jiang H, Zhu HJ. Genome-wide pQTL analysis of protein expression regulatory networks in the human liver. BMC Biol. 2020;18(1):97.
    OpenUrl
  63. ↵
    Syreeni A, Sandholm N, Sidore C, Cucca F, Haukka J, Harjutsalo V, et al. Genome-wide search for genes affecting the age at diagnosis of type 1 diabetes. J Intern Med. 2021;289(5):662–74.
    OpenUrlCrossRef
  64. ↵
    Smith CL, Eppig JT. The mammalian phenotype ontology: enabling robust annotation and comparative analysis. Wiley Interdiscip Rev Syst Biol Med. 2009;1(3):390–99.
    OpenUrlCrossRefPubMed
  65. ↵
    Dixon CI, Walker SE, King SL, Stephens DN. Deletion of the gabra2 gene results in hypersensitivity to the acute effects of ethanol but does not alter ethanol self administration. PLoS One. 2012;7(10):e47135.
    OpenUrlCrossRefPubMed
  66. ↵
    Newman EL, Smith KS, Takahashi A, Chu A, Hwa LS, Chen Y, et al. α2-containing GABA(A) receptors: a requirement for midazolam-escalated aggression and social approach in mice. Psychopharmacology (Berl). 2015;232(23):4359–69.
    OpenUrl
  67. ↵
    Pierucci-Lagha A, Covault J, Feinn R, Nellissery M, Hernandez-Avila C, Oncken C, et al. GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology. 2005;30(6):1193–203.
    OpenUrlCrossRefPubMedWeb of Science
  68. Pierucci-Lagha A, Covault J, Feinn R, Khisti RT, Morrow AL, Marx CE, et al. Subjective effects and changes in steroid hormone concentrations in humans following acute consumption of alcohol. Psychopharmacology (Berl). 2006;186(3):451–61.
    OpenUrlCrossRefPubMed
  69. ↵
    Herman MA, Quadir SG. Pharmacology of Alcohol Use. Reference Module in Biomedical Sciences. Elsevier; 2021.
  70. ↵
    Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018;27(1):113–24.
    OpenUrlCrossRef
Back to top
Posted November 22, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Is anxiety a pathway to Alcohol Use Disorders? A phenome-wide association study of the GABRA2 coding variant rs279858
Alison K. Merikangas, Rachel L. Kember, Martin H. Plawecki, Chella Kamarajan, Grace Chan, Lance Bauer, Jacquelyn L. Meyers, John I. Nurnberger Jr, John Kramer, Bernice Porjesz, Howard J. Edenberg, Laura Almasy
medRxiv 2022.11.21.22282301; doi: https://doi.org/10.1101/2022.11.21.22282301
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area